Bi-Yun Wang (Biyun Wang)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 16

Top Topics

Endoplasmic Reticulum

Estrogen Receptor

Metastatic Breast Cancer

Top Venues

Therapeutic advances in medical oncology

Cancer medicine

Therapeutic advances in drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Shuhui You, Yizhao Xie, Mengjing Ji, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shihui Hu, Yumeng Li, Zhongyi Yang, Bi-Yun Wang
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors. Therapeutic advances in medical oncology 15 (2023)
Shuhui You, Yizhao Xie, Mengjing Ji, Cheng Liu, Yannan Zhao, Chengcheng Gong, Shihui Hu, Yumeng Li, Zhongyi Yang, Bi-Yun Wang
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors. Therapeutic advances in medical oncology 15 (2023)
Xin-Yu Chen, Bin Li, Ye Wang, Juan Jin, Yu Yang, Lei-Huan Huang, Meng-Di Yang, Jian Zhang, Bi-Yun Wang, Zhi-Ming Shao, Ting Ni, Sheng-Lin Huang, Xi-Chun Hu, Zhong-Hua Tao
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. Cancer communications (London, England) (2023)
Shuhui You, Die Sang, Fei Xu, Ting Luo, Peng Yuan, Yizhao Xie, Bi-Yun Wang
Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study. Therapeutic advances in medical oncology 15 (2023)
Yijia Hua, Wei Li, Nan Jin, Dongyan Cai, Jie Sun, Chunxiao Sun, Fan Yang, Xinyu Wu, Xiang Huang, Bi-Yun Wang, Yongmei Yin
Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study. Therapeutic advances in medical oncology 14 (2022)
Yizhao Xie, Cheng Liu, Yannan Zhao, Chengcheng Gong, Yi Li, Shihui Hu, Shaoli Song, Xi-Chun Hu, Zhongyi Yang, Bi-Yun Wang
Heterogeneity derived from 18 F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients. Cancer medicine 11 (9) (2022)
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Bi-Yun Wang
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data. Therapeutic advances in drug safety 13 (2022)
Yizhao Xie, Xinyue Du, Yannan Zhao, Chengcheng Gong, Shihui Hu, Shuhui You, Shaoli Song, Xichun Hu, Zhongyi Yang, Bi-Yun Wang
Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18 F-FES PET. Cancers 14 (14) (2022)
Dou-Dou Li, Zhong-Hua Tao, Bi-Yun Wang, Lei-Ping Wang, Jun Cao, Xi-Chun Hu, Jian Zhang
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial. NPJ breast cancer 8 (1) (2022)
Chengcheng Gong, Cheng Liu, Zhonghua Tao, Jian Zhang, Leiping Wang, Jun Cao, Yannan Zhao, Yizhao Xie, Xichun Hu, Zhongyi Yang, Bi-Yun Wang
Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18 F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer. Cancers 14 (16) (2022)
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Bi-Yun Wang
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data. Therapeutic advances in drug safety 13 (2022)
Bi-Yun Wang, Tao Sun, Yannan Zhao, Shusen Wang, Jian Zhang, Zhonghua Wang, Yue-E Teng, Li Cai, Min Yan, Xiaojia Wang, Zefei Jiang, Yueyin Pan, Jianfeng Luo, Zhimin Shao, Jiong Wu, Xiaomao Guo, Xi-Chun Hu
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. Nature communications 13 (1) (2022)
Yannan Zhao, Ning Xie, Wei Li, Wenyan Chen, Zheng Lv, Yabing Zheng, Tao Sun, Jieqiong Liu, Jian Zhang, Shihui Hu, Yajun Wang, Chengcheng Gong, Yi Li, Yizhao Xie, Rui Ge, Fei Xu, Bi-Yun Wang
Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study. Therapeutic advances in medical oncology 13 (2021)
Yi Li, Wei Li, Chengcheng Gong, Yabin Zheng, Quchang Ouyang, Ning Xie, Qing Qu, Rui Ge, Bi-Yun Wang
A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer. Therapeutic advances in medical oncology 13 (2021)
Yizhao Xie, Rui Ge, Die Sang, Ting Luo, Wei Li, Xuening Ji, Peng Yuan, Bi-Yun Wang
Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study. Cancer medicine 9 (9) (2020)
Yannan Zhao, Yi Li, Chengcheng Gong, Yizhao Xie, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Bi-Yun Wang, Xichun Hu
Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer. Cancer medicine 9 (23) (2020)